Tenofovir Alafenamide

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 4122 publications

Lenacapavir as pre-exposure prophylaxis for HIV prevention.

Lenacapavir as pre-exposure prophylaxis for HIV prevention.

Journal: The Cochrane database of systematic reviews

Published: April 01, 2026

Investigation of the effects of antivirals used in hepatitis B treatment on blood lipid profile: a retrospective real-life data analysis.

Investigation of the effects of antivirals used in hepatitis B treatment on blood lipid profile: a retrospective real-life data analysis.

Journal: Minerva gastroenterology

Published: March 18, 2026

Fracture risk assessment in patients prescribed pre-exposure prophylaxis for HIV: An audit and comparative evaluation of screening tools.

Fracture risk assessment in patients prescribed pre-exposure prophylaxis for HIV: An audit and comparative evaluation of screening tools.

Journal: International journal of STD & AIDS

Published: March 17, 2026

Atorvastatin suppresses HIV/antiretroviral drug-induced cardiac fibrosis and dysfunction in mice by blocking platelet TGFβ1 signaling.

Atorvastatin suppresses HIV/antiretroviral drug-induced cardiac fibrosis and dysfunction in mice by blocking platelet TGFβ1 signaling.

Journal: JCI insight

Published: March 03, 2026

Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial.

Body Composition Changes in Children Living With HIV Initiated on Dolutegravir or Protease Inhibitors in the CHAPAS-4 Trial.

Journal: The Pediatric infectious disease journal

Published: February 24, 2026

Large-scale sequencing study of de novo regulatory Tandem Repeats (TRs) identifies new ASD (Autism Spectrum Disorders) candidate genes integrating gene expression mapping, brain scRNA-seq and organoid models.

Large-scale sequencing study of de novo regulatory Tandem Repeats (TRs) identifies new ASD (Autism Spectrum Disorders) candidate genes integrating gene expression mapping, brain scRNA-seq and organoid models.

Journal: Research square

Published: February 23, 2026

Correction: Bhola et al. An Integrative Bioinformatics Approach to Investigating TIMP3 and Immune Cell Infiltration: Prognostic and Clinicopathological Implications. Int. J. Mol. Sci. 2025, 26, 8867.

Correction: Bhola et al. An Integrative Bioinformatics Approach to Investigating TIMP3 and Immune Cell Infiltration: Prognostic and Clinicopathological Implications. Int. J. Mol. Sci. 2025, 26, 8867.

Journal: International journal of molecular sciences

Published: February 06, 2026

Corrigendum to "Systemic delivery of tenofovir alafenamide using dissolving and implantable microneedle patches" [Mater. Today Bio 13 (2022) 100217].

Corrigendum to "Systemic delivery of tenofovir alafenamide using dissolving and implantable microneedle patches" [Mater. Today Bio 13 (2022) 100217].

Journal: Materials today. Bio

Published: February 02, 2026

Mitophagic activity and protein levels differ across and within muscles: implications for future skeletal muscle mitophagy research.

Mitophagic activity and protein levels differ across and within muscles: implications for future skeletal muscle mitophagy research.

Journal: Autophagy

Published: January 28, 2026

Hypofractionated radiotherapy across cancer sites: a narrative review of evidence and implementation.

Hypofractionated radiotherapy across cancer sites: a narrative review of evidence and implementation.

Journal: Japanese journal of clinical oncology

Published: January 27, 2026

The effectiveness of the QUAD shot regimen for advanced head and neck squamous cell carcinoma: a multicenter prospective observational study (JROSG 18-2).

The effectiveness of the QUAD shot regimen for advanced head and neck squamous cell carcinoma: a multicenter prospective observational study (JROSG 18-2).

Journal: Practical radiation oncology

Published: January 15, 2026

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

Fixed-dose daily doravirine (100 mg) with islatravir (0·25 mg) versus bictegravir, emtricitabine, and tenofovir alafenamide for initial HIV-1 therapy: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial.

Journal: The lancet. HIV

Published: January 12, 2026

Showing 1-12 of 4,122

Last Updated: 04/28/2026